Recent Updates
Recently added Catalysts
CBLL Positive Sentiment Score: 70/100

Ceribell to Participate in Upcoming March Investor Conferences

Key Takeaway: Ceribell, Inc. has announced its participation in two upcoming investor conferences, enhancing its visibility within the industry. CFO Scott Blumberg will present at the Raymond James 47th Annual Institutional Investors Conference on March 2, and both Scott Blumberg and CEO Jane Chao will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3. The company focuses on innovative solutions for diagnosing and managing serious neurological conditions, emphasizing the capabilities of its FDA-cleared Ceribell System.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell will present at two significant investor conferences.
  • Participation may enhance visibility and interest in Ceribell’s innovative technology.
  • Ceribell’s system has FDA clearance, indicating established safety and efficacy.

Full Press Release Details

SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026, at 1:00 p.m. Pacific Standard Time / 4:00 p.m. Eastern Standard Time. Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:50 a.m. Pacific Standard Time / 1:50 p.m. Eastern Standard Time.
Event: Raymond James 47th Annual Institutional Investors Conference
Date: Monday, March 2, 2026
Time: 1:00 p.m. PST / 4:00 p.m. EST
Event: TD Cowen 46th Annual Health Care Conference
Date: Tuesday, March 3, 2026
Time: 10:50 a.m. PST / 1:50 p.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Brian Johnston or Laine Morgan

Frequently Asked Questions

What is CeriBell, Inc. focused on?

CeriBell, Inc. focuses on transforming the diagnosis and management of serious neurological conditions.

When is the Raymond James conference presentation?

The Raymond James conference presentation is on March 2, 2026, at 1:00 p.m. PST.

Who will speak at the TD Cowen conference?

Scott Blumberg and Jane Chao, Ph.D., will participate in a fireside chat.

What does the Ceribell System do?

The Ceribell System enables rapid diagnosis and monitoring of neurological conditions.

Is the Ceribell System FDA-cleared?

Yes, the Ceribell System is FDA-cleared for detecting seizure and delirium.

Last updated: Feb 18, 2026